Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2016-08-27T04:08:18Z | - |
dc.date.available | 2016-08-27T04:08:18Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 1074-2484 | * |
dc.identifier.issn | 1940-4034 | * |
dc.identifier.other | OAK-15779 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217692 | - |
dc.description.abstract | Objective: Pregnane X receptor (PXR) is a transcriptional regulator of many drug-metabolizing enzymes including cytochrome P450 (CYP) 2C9. The objective of this study was to assess the possible association between PXR single-nucleotide polymorphisms (SNPs) and stable warfarin doses. Methods: A total of 201 patients with stable warfarin doses from the EwhA-Severance Treatment (EAST) Group of Warfarin were included in this study. The influence of genetic polymorphisms on stable warfarin doses was investigated by genotyping 11 SNPs, that is, vitamin K epoxide reductase complex 1 (VKORC1) rs9934438, CYP2C9 rs1057910, CYP4F2 rs2108622, constitutive androstane receptor (CAR) rs2501873, hepatocyte nuclear factor 4 (HNF4) rs3212198, and PXR (rs3814055, rs1403526, rs3732357, rs3732360, rs2276707 and rs2472682). Subgroup analysis was conducted on CYP2C9 wild-type homozygote allele (AA) carriers. Results: One PXR SNP of rs2472682 (A>C) exhibited significant association with stable warfarin doses in study population and the subgroup; variant homozygote carriers required significantly lower daily doses of warfarin than those carrying wild allele by about 0.8 mg. Approximate 43.7% of overall interindividual variability in warfarin dose requirement was explained by multivariate regression model. VKORC1, CYP2C9, age, CYP4F2, PXR rs2472682, and CAR/HNF4 rs2501873/rs3212198 accounted for 29.6%, 5.9%, 3.7%, 2.3%, 1.3%, and 0.9% of the variability, respectively. PXR SNP of rs2472682 remained a significant factor in CYP2C9 wild-type homozygote carriers based on univariate and multivariate analyses. The combination of CAR/HNF4/PXR SNPs of rs2501873/rs3212198/rs2472682 showed about 1 mg dose difference between grouped genotypes in study population and subgroup. Conclusion: Our results revealed that PXR could be a determinant of stable warfarin doses. | * |
dc.language | English | * |
dc.publisher | SAGE PUBLICATIONS INC | * |
dc.subject | warfarin | * |
dc.subject | single-nucleotide polymorphism | * |
dc.subject | transcription factor | * |
dc.subject | CYP2C9 | * |
dc.subject | PXR | * |
dc.title | Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 20 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 532 | * |
dc.relation.lastpage | 538 | * |
dc.relation.journaltitle | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS | * |
dc.identifier.doi | 10.1177/1074248415578906 | * |
dc.identifier.wosid | WOS:000362597500002 | * |
dc.identifier.scopusid | 2-s2.0-84943607333 | * |
dc.author.google | Moon, Jung Yeon | * |
dc.author.google | Chang, Byung Chul | * |
dc.author.google | Lee, Kyung Eun | * |
dc.author.google | Bang, Jun Seok | * |
dc.author.google | Gwak, Hye Sun | * |
dc.date.modifydate | 20240422115307 | * |